BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/25/2020 2:44:05 PM | Browse: 733 | Download: 1035
 |
Received |
|
2020-09-11 17:53 |
|
Peer-Review Started |
|
2020-09-11 17:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-30 06:55 |
|
Revised |
|
2020-10-01 09:21 |
|
Second Decision |
|
2020-10-29 11:00 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-02 04:15 |
|
Articles in Press |
|
2020-11-02 04:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-10 09:00 |
|
Publish the Manuscript Online |
|
2020-11-25 14:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alessandra Mangia, Giovanni Cenderello, Gabriella Verucchi, Alessia Ciancio, Andrea Fontana, Valeria Piazzolla, Nicola Minerva, Maria Maddalena Squillante and Massimiliano Copetti |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alessandra Mangia, MD, N/A, N/A, Liver Unit, Department of Medical Sciences, Fondazione IRCCS “Casa Sollievo della Sofferenza”, viale Cappuccini,1, San Giovanni Rotondo 71013, Italy. a.mangia@tin.it |
| Key Words |
Hepatitis C virus; Hepatitis B virus; Cirrhosis; COVID-19; Sofosbuvir; Velpatasvir |
| Core Tip |
This ongoing study aims to investigate the potential reciprocal influence of coronavirus disease 2019 (COVID-19) and pre-existing cirrhosis. To date, it has included 332 patients with COVID-19 admitted to three Italian hospitals during the current pandemic, as well as two large cohorts of hepatitis C virus (HCV) patients from real-world antiviral treatment (pangenotypic sofosbuvir/velpatasvir combination) studies. Despite the limited COVID-19 sample size, cirrhosis was found to be associated with higher mortality, with the majority of deaths related to cirrhosis of metabolic origin. The very low prevalence of COVID-19 in the HCV cohorts supports a possible protective role of HCV antibodies. |
| Publish Date |
2020-11-25 14:44 |
| Citation |
Mangia A, Cenderello G, Verucchi G, Ciancio A, Fontana A, Piazzolla V, Minerva N, Squillante MM, Copetti M. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? World J Clin Cases 2020; 8(22): 5831-5834 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i22/5831.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i22.5831 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
